How to improve the care of patients with metastatic breast cancer?

Pfizer Inc. and the Latin American Union Against Women's Cancer (ULACCAM) announced the adoption and promotion at the regional level of five measures to address the most pressing gaps in treatment and care. cancer treatment. metastatic bad (CMM).

You may be interested in: How to prevent bad cancer?

Worldwide, nearly 50% of CMM cases and 58% of deaths occur in less developed countries. In Latin America, the need to care for these patients is even deeper and needs more attention. A small number of countries, including Brazil, Mexico, and Peru, specifically consider CMM in their public policies, and no Latin American country has specific plans for these patients, according to the report. Latin American metastatic bad cancer survey conducted by IPSOS (Ipsos Public Affais). Market Study.)

"We are proud of the tremendous progress we have made globally in the care of patients with early-stage bad cancer, but we can not say the same with care for patients with CMM, a condition that also affects men, albeit to a lesser extent, "said Marta Mattiussi, president of MACMA, a member organization of ULACCAM. "The" Mission Against Clock "initiative seeks to change this reality in collaboration with other people wishing to have a positive impact on the future of CMM patients."

The five measures published in the Mission Against Clock statement came out of the June Cancún, Mexico Summit, in which 25 patient organizations from 9 Latin American countries agreed to work together. together for:

– double the overall average survival of patients with MCM by 2025. 19659002] – Improved availability of robust epidemiology and data on CMM.

– Improving the quality of life of patients with MCM in clinical practice.

– Increased availability and access to multidisciplinary care.

– Provide specific and accurate information tools on CMM.

The five regional priorities cited taking into account the 10 global priorities defined by the so-called ABC Global Charter. This global alliance bases its work on the world report of the decade, a multidisciplinary report badyzing the situation of MWC in the world during the decade 2005-2015.

"With Mission Against Clock, we are looking to dramatically increase support, access to resources, and outcomes in the treatment of CMM patients – our goal is to leave no patient with this condition." said Luis Alberto Suárez, medical director of the division of Pfizer oncology for Latin America.

The regional priorities adopted at the Cancún summit and communicated as part of the global month for the fight against bad cancer, corresponds to the results of the Latin American survey on digital metastatic bad cancer carried out by IPSOS (consulting Ipsos Public Affairs Market Research) for Pfizer between April and May, in which twenty-eight representatives of non-governmental organizations participated in nine Latin American countries: Argentina, Brazil, Chile, Colombia, Costa Rica , Ecuador, Guatemala, Mexico and Peru.

This search revealed the following data

– 79% of respondents said that there was no CMM-specific registration code

– 64% think that There is fragmented coordination between the different actors responsible for care. CMM patients within health systems.

– 93% said that caregiver or family caregiver tools for CMM patients do not exist or do not exist, but that they do not exist. were not known

Promote awareness and public education efforts on the CMM. Pfizer invites governments, patient organizations, medical societies, patients, their families and the media to work together to achieve the goals set for 2025.

For its part, ULACCAM will continue its efforts to provide visibility. to the five regional priorities that seek to generate the necessary sense of urgency among those who develop and define the public policies that affect CMM patients. During the month of October, ULACCAM and its member organizations will run campaigns in social networks, events and calls. to promote the "Mission Against Time" initiative

You may be interested in: